- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04379739
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer
Neoadjuvant Camrelizumab Plus Apatinib or Platinum-based Chemotherapy for Potentially Resectable (Resectable and Initially Unresectable) II-III Non-small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Detailed Description:
This is a multiple-canter, open-label, phase II trial, 2-4 cycles treatment will be planned as neo-adjuvant therapy for NSCLC participants in stage II-III.
Study design:
Participants: Newly diagnosed Resectable and Initially Unresectale II-III NSCLC without EGFR/ALK mutation.
Treatment:
Group A:camrelizumab 200 mg q3w i.v. for 2-4 cycles, platinum-based chemotherapy q3w i.v for 2-4 cycles before surgery.
Group B:camrelizumab 200 mg q3w i.v. for 2-4 cycles, apatinib 250mg qd po 3w/cycle for 2-4 cycles before surgery;
Endpoints:
Primary objectives are to assess MPR and safety. Secondary objective is to assess 2-year overall survival (OS), disease-free survival (DFS), OS etc.
Exploratory end point is to explore biomarkers.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shang'ai, Shanghai, China, 200433
- Shanghai Pulmonary Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Group A:
- Aged 18-75 years;
- Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1;
- Histological or cytological diagnosis of NSCLC by needle biopsy, and clinical stage II-III according to the TNM classification (8th edition) validated by radiological examination or EBUS;
- At least 1 measurable lesion according to RECIST 1.1;
- Life expectancy is at least 12 weeks;
Adequate hematological function, liver function and renal function:
- Hemoglobin ≤ 90 g/L (which can be maintained or exceeded by blood transfusion);
- Absolute neutrophil count (ANC) ≤ 1.5 *10^9/L;
- Platelet count ≤ 100 * 10^9/L;
- Total bilirubin ≤ 1.5 times of upper limit of normal (ULN);
- Alanine glutamate transaminase (ALT), straw glutamate transaminase (AST) and alkaline phosphatase (ALP) ≤ 2.5 * ULN;
- Creatinine ≤ 1.5 * ULN, Creatinine clearance rate ≤ 60ml/min;
- The international standardized ratio of prothrombin time (INR) ≤ 1.5 R in patients who have not received anticoagulation therapy, and the partial thrombin time (APTT) ≤ 1.5 * ULN.
- Without systemic metastasis (including M1a, M1b and M1c);
- With the expectation of radical surgery therapy, or with the expectation of complete resection after treatment;
- Patients with normal lung function can tolerate surgery;
- The child-bearing female must undergo pregnancy test (serum or urine) within 72 hours before drug administrating and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 90 days after the last dosage of the drug. The male participants whose partners are child-bearing shall use condom for contraception during the trial and within 30 days after completion of the trial;
- Signed and dated informed consent.
Group B:
- Aged 18-75 years;
- Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1;
- Histological or cytological diagnosis of NSCLC by needle biopsy, and clinical stage II-III according to the TNM classification (8th edition) validated by radiological examination or EBUS;
- Enough tumor samples from biopsy to testing PD-L1 expression level, and PD-L1 ≥ 1%
- At least 1 measurable lesion according to RECIST 1.1;
- Life expectancy is at least 12 weeks;
Adequate hematological function, liver function and renal function:
- Hemoglobin ≤ 90 g/L (which can be maintained or exceeded by blood transfusion);
- Absolute neutrophil count (ANC) ≤ 1.5 *10^9/L;
- Platelet count ≤ 100 * 10^9/L;
- Total bilirubin ≤ 1.5 times of upper limit of normal (ULN);
- Alanine glutamate transaminase (ALT), straw glutamate transaminase (AST) and alkaline phosphatase (ALP) ≤ 2.5 * ULN;
- Creatinine ≤ 1.5 * ULN, Creatinine clearance rate ≤ 60ml/min;
- The international standardized ratio of prothrombin time (INR) ≤ 1.5 R in patients who have not received anticoagulation therapy, and the partial thrombin time (APTT) ≤ 1.5 * ULN.
- Without systemic metastasis (including M1a, M1b and M1c);
- With the expectation of radical surgery therapy, or with the expectation of complete resection after treatment;
- Patients with normal lung function can tolerate surgery;
- The child-bearing female must undergo pregnancy test (serum or urine) within 72 hours before drug administrating and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 90 days after the last dosage of the drug. The male participants whose partners are child-bearing shall use condom for contraception during the trial and within 30 days after completion of the trial;
- Signed and dated informed consent.
Exclusion Criteria:
Group A:
- The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment, immunotherapy or Chinese medicine treatment, etc. (excluding the malignant tumors that were resected radically and did not recurrent more than 5 years);
- Non-squamous cell carcinoma with EGFR active mutation positive or ALK rearrangement;
- The patient suffered from other cancers (except cervical carcinoma in situ, cured basal cell carcinoma and bladder epithelial tumor [including Ta and Tis]) within 5 years before the enrollment;
- The patient suffers from any active autoimmune disease or have the history of autoimmune disease, such as uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy), tuberculosis; Note: The patients with complete remission of childhood asthma and without any interventions in adult life could be included. The patients with skin diseases (like vitiligo, psoriasis or alopecia) who do not need systematic therapy could be included.
- Suffering or having the history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiological pneumonia, drug-induced pneumonia, radiologically confirmed active pneumonia, or severe impairment of lung function;
- Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/ day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy with a dose of less than 10 mg/ day of prednisone are permitted;
- Allergy to the test drug;
- The patient is a carrier of active hepatitis B, hepatitis C or HIV;
- Pregnancy or breast-feeding women; child-bearing participants who could not or are unwilling to take contraceptive measures.
- Patients with eurological or psychiatric disorders history were lack of treatment compliance;
- Other situations in which investigators thought the patients not suit to be included.
Group B:
- The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment, immunotherapy or Chinese medicine treatment, etc. (excluding the malignant tumors that were resected radically and did not recurrent more than 5 years);
- Non-squamous cell carcinoma with EGFR active mutation positive or ALK rearrangement;
- The patient suffered from other cancers (except cervical carcinoma in situ, cured basal cell carcinoma and bladder epithelial tumor [including Ta and Tis]) within 5 years before the enrollment;
- The patient suffers from any active autoimmune disease or have the history of autoimmune disease, such as uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy), tuberculosis; Note: The patients with complete remission of childhood asthma and without any interventions in adult life could be included. The patients with skin diseases (like vitiligo, psoriasis or alopecia) who do not need systematic therapy could be included.
- Suffering or having the history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiological pneumonia, drug-induced pneumonia, radiologically confirmed active pneumonia, or severe impairment of lung function;
- Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/ day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy with a dose of less than 10 mg/ day of prednisone are permitted;
- Imaging (CT or MRI) shows that the tumor has invaded or blurred the boundary with the great vessels;
- The participants who suffered thrombus events, such as stroke (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;
- Having clinically significant bleeding symptoms or had definite bleeding tendency, such as gastrointestinal bleeding or bleeding ulcer, or were receiving thrombolytic therapy or anticoagulant therapy within 3 months before enrollment;
- Having symptoms of obvious hemoptysis or daily hemoptysis of 2.5ml or more within 1 month before enrollment;
- Participants with hypertension and unable to obtain good control with antihypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); Grade II or larger myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including QTc interphase, male ≥ 450ms, female ≥ 470ms); According to NYHA, grade Ⅲ ~ Ⅳ cardiac insufficiency, or left ventricular ejection fraction (LVEF) < 50%;
- The participants have undergone other major systemic operations or suffered from severe trauma within 2 months before the enrollment;
- Urinary protein ≥ ++, or urinary protein ≥1g at 24h or severe liver and kidney dysfunction;
- Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage;
- Allergy to the test drug;
- The patient is a carrier of active hepatitis B, hepatitis C or HIV;
- Pregnancy or breast-feeding women; child-bearing participants who could not or are unwilling to take contraceptive measures.
- Patients with eurological or psychiatric disorders history were lack of treatment compliance;
- Other situations in which investigators thought the patients not suit to be included.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: camrelizumab + apatinib
Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; apatinib 250 mg, qd, p.o. 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation. Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment. Adjuvant treatment stage: according to the NCCN guidelines. |
camrelizumab 200mg, q3w, i.v., 2-4 cycles;
Other Names:
|
Experimental: camrelizumab + platinum-based chemotherapy
Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (squamous: carboplatin AUC5, gemcitabine 1000mg/m2; non-squamous: carboplatin AUC5, pemetrexed 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation. Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment. Adjuvant treatment stage: according to the NCCN guidelines. |
camrelizumab 200mg, q3w, i.v., 2-4 cycles;
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major pathologic response (MPR)
Time Frame: up to 5 months
|
MPR is defined as the proportion of participants who have achieved major pathologic response (on routine hematoxylin and eosin staining, tumors with no more than 10% viable tumor cells) in all participants who have completed the neoadjuvant therapy before surgery.
|
up to 5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-year OS
Time Frame: up to 27 months
|
It is defined as the time from enrollment to death of participant due to any cause in 2 years.
In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date.
|
up to 27 months
|
Objective response rate (ORR)
Time Frame: up to 4 months
|
It refers to the proportion of patients who have had a complete response or partial response (according to RECIST1.1) as confirmed by CT evaluation after 3 weeks in all patients who have completed the neoadjuvant therapy.
Only patients with measurable lesions at baseline will be analyzed.
|
up to 4 months
|
Disease-free survival (DFS)
Time Frame: up to 60 months
|
It refers to the time from radical surgery to relapse or death of a participant due to disease progression.
In the case of a patient who still survives at the time of analysis, the latest evaluation date will be used for interpolation (censoring).
|
up to 60 months
|
Overall survival (OS)
Time Frame: up to 63 months
|
It is defined as the time from enrollment to death of participant due to any cause.
In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date.
In the event of a patient with the survival status unknown, the date when the patient is last known to be alive will be used for interpolation (censoring).
|
up to 63 months
|
Safety: frequency of severe adverse events
Time Frame: up to 6 months
|
The frequency of severe adverse events from the participants enrolling to 90 days after the last drug administration or 30 days after surgery or new anti-cancer therapy, which comes first.
|
up to 6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
- MA-NSCLC-II-001 (LungMate-003)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
Genelux CorporationNewsoara Biopharma Co., Ltd.Not yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
Clinical Trials on Camrelizumab
-
Shandong Provincial HospitalUnknown
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalNot yet recruitingUterine Cervical Neoplasms | Oncolytic Virotherapy | CamrelizumabChina
-
Fujian Medical University Union HospitalRecruitingRadiotherapy | Immunotherapy | Esophageal NeoplasmChina
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
Peking UniversityNot yet recruiting
-
Hebei Medical University Fourth HospitalRecruiting
-
Nanfang Hospital of Southern Medical UniversityRecruitingNasopharyngeal Carcinoma | Oligometastasis | RadiotherapyChina
-
Henan Provincial People's HospitalNot yet recruiting
-
Fudan UniversityRecruiting